 |
Vol.64 No.1 contents | Japanese/English |
 | Full Text of PDF (2238K) Article in Japanese |
- Invited Review Article -
Future Direction of the Development of Immunotherapy for Lung Cancer
Tatsuya Yoshida1,21Department of Thoracic Oncology, 2Department of Experimental Therapeutics, National Cancer Center Hospital, Japan
Immune checkpoint inhibitors (ICIs), such as anti-programmed death receptor-1/programmed death ligand 1 (PD/PD-L1) antibody monotherapy and in combination with chemotherapy, have shown favorable efficacy compared with chemotherapy alone in several phase III trials for advanced non-small cell lung cancer (NSCLC) and have become the standard of care. Recently, the indication for ICIs has expanded to include the perioperative treatment for early-stage NSCLC cancer and first-line treatment for small cell lung cancer. However, there are still many cases in which ICIs are not effective, or where resistance is observed after an initial response to ICIs. In addition, the PD-L1 expression on tumor cells, which has been a biomarker of ICIs susceptibility, cannot reliably predict the therapeutic efficacy of immunotherapy. Thus, the further development of novel immunotherapies and identification of biomarkers of ICI susceptibility are warranted. In this article, we review the current status of and issues associated with cancer immunotherapy in lung cancer, the potential utility of novel immunotherapies, such as novel ICIs and bispecific T-cell engager, and the future direction of the development of biomarkers for immunotherapy in lung cancer patients.
key words: Lung cancer, Immune checkpoint inhibitor, Anti-PD-(L)1 antibody, Anti-CTLA-4 antibody, Bispecific T-cell engager
JJLC 64 (1): 2-10, 2024
